HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 108-111

  Buti, Maria ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

HBeAg positive; Nucleoside analogues; Therapy

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; NUCLEOSIDE ANALOG; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CANCER RISK; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HISTORY; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MEDICATION COMPLIANCE; QUALITY OF LIFE; REVIEW; SEROCONVERSION; TREATMENT RESPONSE;

HBEAG POSITIVE; NUCLEOSIDE ANALOGUES; THERAPY;

ADENINE; AGE FACTORS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; LAMIVUDINE; NUCLEOSIDES; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SEX FACTORS; THYMIDINE; TREATMENT OUTCOME;

EID: 84890865159     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12392     Document Type: Review

References (35)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
2. Berg T, Benhamou Y, Calleja JL, et al. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat 2010; 17: 624-30.
3. Chen CJ, Yang HI, Su J, et al.; REVEAL HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
4. Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL Revealed? Liver Int 2012; 32: 1333-41.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
6. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
7. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
8. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
9. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
10. Janssen HL, Van ZM, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
11. Chang TT, Lai CL, Kew YS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-30.
12. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381; 468-75.
13. Van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
14. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
15. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
17. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-8.
18. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-6.
19. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fi brosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
20. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
21. Kim W.R., Berg T., Loomba R. et al. Long term tenofovir disoproxil fumarate therapy and the risk of hepatocellular carcinoma. J Hepatol 2013; 58: S19.
22. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013; 57: 399-408.
23. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-38.
24. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
25. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 1945-53.
26. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
27. Yuan HJ, et al. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. J Infection 2007; 54: 497.
28. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
29. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
30. Heathcote EJ, Gane EJ, Man R, et al. Long-term efficacy and dsafety of Tenofovir disoproxil fumarate treatment in HBeAg positive patients with chronic hepatitis B (study 103). Preliminary analisis Hepatology 2010; 52: 556A.
31. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 2011; 53: 1486-93.
32. Marcellin P, Heathcote EJ, Buti M, et al. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol 2011; 54: S297.
33. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-20.
34. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-95.
35. Gane EJ, Deary G, Piratvisuth T, et al. Renal function is improved for chronic hepatitis B (CHB) patients treated with telbivudine. Hepatology 2011; 54(Suppl): 1044A.